Rani Therapeutics Holdings, Inc. (RANI)

Market: NASD | Currency: USD

Address: 2051 Ringwood Avenue

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment Show more

📈 Rani Therapeutics Holdings, Inc. Historical Chart

📊 Statistics

Analyst 1 Year Price Target: $7.80
Upside/Downside from Analyst Target: 1,435.43%
Broker Call: 8
Dividend Minimum 3 Year Yield: 0.00%
EPS Growth Range (1Y): 10-25%
Net Income Growth Range (1Y): 0-10%
Revenue Growth Range (1Y): -

💰 Dividend History

No dividend history available.

📅 Earnings & EPS History for Rani Therapeutics Holdings, Inc.

Date	Reported EPS
2025-05-13	-0.22
2025-03-31	-0.27
2025-03-19	-
2024-11-14	-0.24
2024-08-06	-0.26
2024-08-05	-0.26
2024-05-06	-0.29
2024-05-05	-0.29
2024-03-20	-0.27
2024-03-19	-0.27
2023-11-08	-0.36
2023-11-07	-0.36
2023-08-11	-0.37
2023-08-10	-0.37
2023-05-10	-0.33
2023-05-09	-0.33
2023-03-22	-0.35
2023-03-21	-0.35
2022-11-10	-0.33
2022-11-09	-0.33
2022-08-10	-0.31
2022-08-09	-0.31
2022-05-11	-0.29
2022-05-10	-0.29
2022-03-29	-0.27
2022-03-28	-0.27
2021-11-15	-0.12
2021-09-13	-0.12
2021-09-12	-0.12
2021-08-03	-
2021-08-02	-
2021-08-02	-
2021-08-01	-

📰 Related News & Research

No related articles found for "rani therapeutics".